在NTRK2融合阳性非小细胞肺癌中对拉罗特雷克提尼布的完整反应
Lorenz Frehner1, Simon Haefliger1, Ferdinando Cerciello1
1Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Case reports in oncology
|October 30, 2023
概括
拉罗特雷克提尼布在神经营性受体激酶 (NTRK) 基因2阳性非小细胞肺癌 (NSCLC) 中显示出有效性. 这项案例研究表明,TRK抑制剂可能有利于NTRK2融合的患者,扩大NSCLC的治疗选择.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 非小细胞肺癌 (NSCLC) 治疗可能涉及向神经营养受体激酶 (NTRK) 基因融合.
- 热氨酸激酶 (TRK) 抑制剂对具有NTRK1或NTRK3融合的NSCLC有效.
- 在NTRK2融合的NSCLC中,TRK抑制剂的疗效数据以前没有.
研究的目的:
- 在患有NSCLC和NTRK2融合的患者中报告TRK抑制剂的疗效.
- 研究第一代TRK抑制剂对NTRK2-改变NSCLC的潜力.
主要方法:
- 一个患有晚期NSCLC的女性患者的病例报告.
- 基因组分析以确定NTRK基因融合.
- 用拉罗特雷克提尼布治疗,它是一种TRK抑制剂.
主要成果:
- 患者的NSCLC确实存在一个NTRK2融合.
- 患者实现了对larotrectinib治疗的完整和持续反应.
- 这表明TRK抑制剂在NTRK2-阳性NSCLC中具有显著的临床活性.
结论:
- 拉罗特雷克提尼布在与NTRK2基因融合的NSCLC中显示出有效性.
- 第一代TRK抑制剂可能是NTRK2-改变NSCLC的患者可行的治疗选择.
- 需要对NSCLC中的NTRK2合并进行进一步的调查.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
相关概念视频
01:20The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K